1526 A NEPHROLITHOMETRIC NOMOGRAM FOR PREDICTING TREATMENT SUCCESS IN PERCUTANEOUS NEPHROLITHOTOMY

Authors:

Abstract
Tion in focal atherosclerotic lesions of the internal pudendal arteries (IPAs) among men with erectile dysfunction (ED) and a suboptimal response to phosphodiesterase-5 inhibitors. Zotarolimus is a cytostatic limus drug that minimizes growth of restenotic cells and preserves healthy endothelial cells lining a cobalt chromium stent. METHODS: We performed a prospective, multicenter, singlearmed safety and feasibility trial of 30 male subjects Ͼ 18 years with atherosclerotic ED and a suboptimal response to phosphodiesterase-5 inhibitors. A novel combination of clinical, duplex ultrasound, and invasive angiographic factors were used to determine eligibility for stent therapy. Key inclusion criteria included IIEF-6 Ͻ 21 with at least 4 weeks of PDE5i use, ultrasound PSVs Ͻ 30 cm/sec bilaterally, and angiographic stenosis of one or both IPAs. Key exclusion criteria included non-vascular causes of ED, venous leak as seen on penile Doppler (EDV Ͼ 5 cm/sec), and arteriographic non target lesions of Ͼ 70% stenosis in common iliac or common penile artery. The primary safety end point was any major adverse event 30 days after the procedure. The primary feasibility end point was improvement in the IIEF-6 (Erectile Dysfunction Domain) score of 4 points or more. RESULTS: Forty-five lesions were treated with stents in 30 subjects. Procedural success was 100% with no major adverse events through follow-up. The primary feasibility end point (IIEF-6 ϩ4) was achieved by 59.3% (16/27) of intention to treat subjects at 3 and 6 months, and 81% of subjects (17/21) at 1 year. Mean peak systolic velocity on penile Doppler increased from 16.4 cm/s at baseline to 28.8 cm/sec at 3 months, 42 cm/sec at 6 months, and 32.4 cm/sec at 1 year. 5 patients were stented outside the pudendal artery and 4 subjects withdrew from follow up. Angiographic binary restonosis (Ͼ50% lumen diameter stenosis) was found in 11/32 lesions (34.4%). CONCLUSIONS: Among patients with ED and limited response with pharmacologic therapy, percutaneous stent revascularization of the internal pudendal artery is safe and appears promising. However, additional research is needed to determine if pudendal artery stenting is a viable adjunctive treatment for men with vasculogenic ED.